Jubilant Epipad LLC has a total of 17 patent applications. Its first patent ever was published in 2018. It filed its patents most often in Australia, Brazil and Canada. Its main competitors in its focus markets pharmaceuticals and organic fine chemistry are SHANGHAI HUILUN LIFE SCIENCE & TECHNOLOGY CO LTD, S C R NEWPHARM and KUNMING PLANT INST CHINESE ACA.
# | Country | Total Patents | |
---|---|---|---|
#1 | Australia | 2 | |
#2 | Brazil | 2 | |
#3 | Canada | 2 | |
#4 | EPO (European Patent Office) | 2 | |
#5 | Israel | 2 | |
#6 | Republic of Korea | 2 | |
#7 | Singapore | 2 | |
#8 | United States | 2 | |
#9 | China | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Heterocyclic compounds | |
#3 | Therapeutic chemical compounds |
# | Name | Total Patents |
---|---|---|
#1 | Rajagopal Sridharan | 13 |
#2 | Duraiswamy Athisayamani Jeyaraj | 13 |
#3 | Hallur Gurulingappa | 13 |
#4 | Purra Buchi Reddy | 13 |
#5 | Rao N V S K | 13 |
#6 | Kristam Rajendra | 6 |
#7 | Buchi Reddy Purra | 2 |
#8 | Sridharan Rajagopal | 2 |
#9 | Gurulingappa Hallur | 2 |
#10 | N V S K Rao | 2 |
Publication | Filing date | Title |
---|---|---|
SG11202003463XA | Imidazo-pyridine compounds as pad inhibitors | |
CN111108105A | Heterocyclic compounds as PAD inhibitors |